Early oncology pacesetters for 2019 will seek to pick up where Janssen left off in 2018

Judging which companies are topping the oncology research charts in any given quarter or year can be highly subjective, but sometimes drugmakers present a series of new findings at once that make their activities hard to ignore.

Certainly in hemato-oncology, the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen had that type of ending to 2018, presenting data at December’s ASH meeting on both its on-market assets and its pipeline candidates that showed serious momentum in blood cancers.

As the 2019 oncology season starts in earnest next week with the American Association for Cancer Research Annual Meeting getting underway, plenty of drugmakers will be hoping to cause a similar impression as they update the world on their latest research.